Skip to content

Clinical trials

Phase 1/2 Lung Neoplasms trials in South Korea

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Phase 1/2 Country / region: South Korea Clear all

17 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20101
20161
20173
20195
20201
20212
20242
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed6
Recruiting6
Active, not recruiting3
Terminated2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company2
Revolution Medicines, Inc.2
Turning Point Therapeutics, Inc.2
AVEO Pharmaceuticals, Inc.1
Frontier Medicines Corporation1
Hoffmann-La Roche1
Incyte Corporation1
Inhibrx Biosciences, Inc1
Merck Sharp & Dohme LLC1
Merrimack Pharmaceuticals1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms17
Carcinoma, Non-Small-Cell Lung16
Neoplasms9
Head and Neck Neoplasms7
Neoplasms by Site7
Colorectal Neoplasms6
Lung Diseases6
Neoplasm Metastasis6
Respiratory Tract Diseases6
Respiratory Tract Neoplasms6

Trials

Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.